{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T18:29:12Z","timestamp":1789410552493,"version":"build-2803163510"},"reference-count":69,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,11,17]],"date-time":"2022-11-17T00:00:00Z","timestamp":1668643200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010711","name":"Sy\u00f6p\u00e4s\u00e4\u00e4ti\u00f6","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010711","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009420","name":"Varsinais-Suomen Sairaanhoitopiiri","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009420","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Established therapies for prostate cancer (PCa), surgery and radiotherapy, treat the entire gland regardless of the location of the cancerous lesion within the prostate. Although effective, these methods include a significant risk of worsening genitourinary outcomes. Targeted image-guided cancer therapy has gained acceptance through improved PCa detection, localization, and characterization by magnetic resonance imaging (MRI). Minimally-invasive ablative techniques aim to achieve comparable oncological outcomes to radical treatment while preserving genitourinary function. Transurethral ultrasound ablation (TULSA) and next-generation transrectal high-intensity focused ultrasound (HIFU) utilize MRI guidance to thermally ablate prostate tissue under real-time MRI monitoring and active temperature feedback control. Previous trials performed by our group and others, including a large multicenter study in men with localized favorable-risk disease, have demonstrated that TULSA provides effective prostate ablation with a favorable safety profile and low impact on quality of life. Recently, MRI-guided HIFU focal therapy was also shown as a safe and effective treatment of intermediate-risk PCa. Here we review the current literature on ablative techniques in the treatment of localized PCa with a focus on TULSA and HIFU methods.<\/jats:p>","DOI":"10.3389\/fonc.2022.1043688","type":"journal-article","created":{"date-parts":[[2022,11,17]],"date-time":"2022-11-17T10:01:34Z","timestamp":1668679294000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Evolving imaging methods of prostate cancer and the emergence of magnetic resonance imaging guided ablation techniques"],"prefix":"10.3389","volume":"12","author":[{"given":"Mikael","family":"Anttinen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Blanco Sequeiros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter J.","family":"Bostr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pekka","family":"Taimen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,11,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.eururo.2019.08.005","article-title":"Recent global patterns in prostate cancer incidence and mortality rates","volume":"77","author":"Culp","year":"2020","journal-title":"Eur Urol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1002\/cncr.32498","article-title":"Prostate cancer in young men: An emerging young adult and older adolescent challenge","volume":"126","author":"Bleyer","year":"2020","journal-title":"Cancer"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.914875","article-title":"Causes of death among prostate cancer patients aged 40 years and older in the united states","volume":"12","author":"Ye","year":"2022","journal-title":"Front Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2019.10.030","article-title":"Ten-year mortality, disease progression, and treatment-related side effects in men with localised prostate cancer from the ProtecT randomised controlled trial according to treatment received","volume":"77","author":"Neal","year":"2020","journal-title":"Eur Urol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(12)70388-1","article-title":"Do low-grade and low-volume prostate cancers bear the hallmarks of malignancy","volume":"13","author":"Ahmed","year":"2012","journal-title":"Lancet Oncol"},{"key":"B6","article-title":"Edn. presented at the EAU annual congress Amsterdam","author":"Guidelines","year":"2022"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2019.20675","article-title":"Patient-reported outcomes through 5 years for active surveillance, surgery, brachytherapy, or external beam radiation with or without androgen deprivation therapy for localized prostate cancer","volume":"323","author":"Hoffman","year":"2020","journal-title":"Jama"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMe2016433","article-title":"Cardiovascular disease and androgen axis\u2013targeted drugs for prostate cancer","volume":"382","author":"Higano","year":"2020","journal-title":"New Engl J Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012663","article-title":"Prostate MRI, with or without MRI-targeted biopsy, and systematic biopsy for detecting prostate cancer","volume":"4","author":"Drost","year":"2019","journal-title":"CochraneDatabase Syst Rev"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30314-7","article-title":"Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): A prospective, randomised, multicentre study","volume":"395","author":"Hofman","year":"2020","journal-title":"Lancet"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(98)00278-7","article-title":"Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases","volume":"52","author":"Sweat","year":"1998","journal-title":"Urology"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-017-3631-6","article-title":"68Ga-PSMA-11 PET\/CT in primary staging of prostate cancer: PSA and Gleason score predict the intensity of tracer accumulation in the primary tumour","volume":"44","author":"Uprimny","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B13","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1111\/bju.14858","article-title":"Detection and localisation of primary prostate cancer using 68gallium prostate-specific membrane antigen positron emission tomography\/computed tomography compared with multiparametric magnetic resonance imaging and radical prostatectomy specimen pathology","volume":"126","author":"Kalapara","year":"2020","journal-title":"BJU Int"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2015.12.025","article-title":"Diagnostic efficacy of 68gallium-PSMA positron emission tomography compared to conventional imaging for lymph node staging of 130 consecutive patients with intermediate to high risk prostate cancer","volume":"195","author":"Maurer","year":"2016","journal-title":"J Urol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000000501","article-title":"Prostate specific membrane antigen targeted positron emission tomography of primary prostate cancer: assessing accuracy with whole mount pathology","volume":"203","author":"Bahler","year":"2020","journal-title":"J Urol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/s41391-020-00292-2","article-title":"Evaluating f-18-PSMA-1007-PET in primary prostate cancer and comparing it to multi-parametric MRI and histopathology","volume":"24","author":"Priv\u00e9","year":"2021","journal-title":"Prostate Cancer prostatic Dis"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1056\/nejmcibr0905562","article-title":"The index lesion and the origin of prostate cancer","volume":"361","author":"Ahmed","year":"2009","journal-title":"New Engl J Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2011.10776.x","article-title":"Quantitative tissue analyses of prostate cancer foci in an unselected cystoprostatectomy series","volume":"110","author":"Nevoux","year":"2012","journal-title":"BJU Int"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22858","article-title":"Prostate cancer laterality as a rationale of focal ablative therapy for the treatment of clinically localized prostate cancer","volume":"110","author":"Mouraviev","year":"2007","journal-title":"Cancer: Interdiscip Int J Am Cancer Soc"},{"key":"B20","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1002\/1097-0142(197207)30","article-title":"Carcinoma of the prostate: prognostic evaluation of certain pathologic features in 208 radical prostatectomies","volume":"30","author":"Byar","year":"1972","journal-title":"Cancer"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2016.07.008","article-title":"Intratumoral and intertumoral genomic heterogeneity of multifocal localized prostate cancer impacts molecular classifications and genomic prognosticators","volume":"71","author":"Wei","year":"2017","journal-title":"Eur Urol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/j.eururo.2018.08.009","article-title":"Multifocal primary prostate cancer exhibits high degree of genomic heterogeneity","volume":"75","author":"L\u00f8vf","year":"2019","journal-title":"Eur Urol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20243","article-title":"Heterogeneity of Gleason grade in multifocal adenocarcinoma of the prostate","volume":"100","author":"Arora","year":"2004","journal-title":"Cancer: Interdiscip Int J Am Cancer Soc"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/0046-8177(92)90106-D","article-title":"Cancer volume and site of origin of adenocarcinoma in the prostate: relationship to local and distant spread","volume":"23","author":"McNeal","year":"1992","journal-title":"Hum Pathol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2010.10039.x","article-title":"Understanding the pathological features of focality, grade and tumour volume of early-stage prostate cancer as a foundation for parenchyma-sparing prostate cancer therapies: active surveillance and focal targeted therapy","volume":"108","author":"Mouraviev","year":"2011","journal-title":"BJU Int"},{"key":"B26","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1089\/end.2009.0462","article-title":"Impact of prostate cancer multifocality on its biology and treatment","volume":"24","author":"Algaba","year":"2010","journal-title":"J Endourol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(02)01728-4","article-title":"Morphologic and clinical significance of multifocal prostate cancers in radical prostatectomy specimens","volume":"60","author":"Wise","year":"2002","journal-title":"Urology"},{"key":"B28","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1038\/pcan.2010.16","article-title":"Histological characteristics of the index lesion in whole-mount radical prostatectomy specimens: implications for focal therapy","volume":"14","author":"Karavitakis","year":"2011","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2015.01.030","article-title":"Focal ablation targeted to the index lesion in multifocal localised prostate cancer: a prospective development study","volume":"68","author":"Ahmed","year":"2015","journal-title":"Eur Urol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2014.08.079","article-title":"Multifocality and prostate cancer detection by multiparametric magnetic resonance imaging: correlation with whole-mount histopathology","volume":"67","author":"Le","year":"2015","journal-title":"Eur Urol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1016\/j.urolonc.2021.04.021","article-title":"Unilateral lesion detected on preoperative multiparametric magnetic resonance imaging and MRI\/US fusion-guided prostate biopsy is not an appropriate indication for focal therapy in prostate cancer","volume":"39","author":"Zhou","year":"2021","journal-title":"In Urol Oncol: Semin Original Investi"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2018.11.031","article-title":"Detection of individual prostate cancer foci via multiparametric magnetic resonance imaging","volume":"75","author":"Johnson","year":"2019","journal-title":"Eur Urol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13000-019-0782-8","article-title":"Histological characteristics of the largest and secondary tumors in radical prostatectomy specimens and implications for focal therapy","volume":"14","author":"Choi","year":"2019","journal-title":"Diagn Pathol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000001389","article-title":"Predicting pathological tumor size in prostate cancer based on multiparametric prostate magnetic resonance imaging and preoperative findings","volume":"205","author":"Pooli","year":"2021","journal-title":"J Urol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2016.07.084","article-title":"Magnetic resonance imaging underestimation of prostate cancer geometry: use of patient specific molds to correlate images with whole mount pathology","volume":"197","author":"Priester","year":"2017","journal-title":"J Urol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1002\/jmri.26727","article-title":"IMPROD biparametric MRI in men with a clinical suspicion of prostate cancer (IMPROD trial): sensitivity for prostate cancer detection in correlation with whole-mount prostatectomy sections and implications for focal therapy","volume":"50","author":"Merisaari","year":"2019","journal-title":"J Magnetic Reson Imaging"},{"key":"B37","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.eururo.2021.08.005","article-title":"An updated systematic review on focal therapy in localized prostate cancer: what has changed over the past 5 years","volume":"81","author":"Hopstaken","year":"2022","journal-title":"Eur Urol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1089\/end.2016.0830","article-title":"Propensity score-matched comparison of partial to whole-gland cryotherapy for intermediate-risk prostate cancer: an analysis of the cryo on-line data registry data","volume":"31","author":"Tay","year":"2017","journal-title":"J Endourol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2021.09.003","article-title":"High intensity focused ultrasound ablation for prostate cancer: Whole versus partial gland ablation","volume":"20","author":"Byun","year":"2022","journal-title":"Clin Genitouri Cancer"},{"key":"B40","doi-asserted-by":"publisher","first-page":"207","DOI":"10.5152\/dir.2019.19157","article-title":"Volumetric MRI-guided, high-intensity focused ultrasound ablation of uterine leiomyomas: ASEAN preliminary experience","volume":"26","author":"Keserci","year":"2020","journal-title":"Diagn Intervent Radiol"},{"key":"B41","article-title":"A technical update of high-intensity focused ultrasound ablation for prostate cancer and benign prostatic hyperplasia","volume":"10","author":"Duc","year":"2018","journal-title":"Imaging Med"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1089\/end.2021.0866","article-title":"Magnetic resonance imaging-guided transurethral ultrasound ablation of prostate cancer: A systematic review","volume":"30","author":"Dora","year":"2022","journal-title":"J Endourol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1080\/21681805.2019.1660707","article-title":"Feasibility of MRI-guided transurethral ultrasound for lesion-targeted ablation of prostate cancer","volume":"53","author":"Anttinen","year":"2019","journal-title":"Scandinavian J Urol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1080\/21681805.2020.1814857","article-title":"Palliative MRI-guided transurethral ultrasound ablation for symptomatic locally advanced prostate cancer","volume":"54","author":"Anttinen","year":"2020","journal-title":"Scandinavian J Urol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.euros.2020.10.007","article-title":"Salvage magnetic resonance imaging\u2013guided transurethral ultrasound ablation for localized radiorecurrent prostate cancer: 12-month functional and oncological results","volume":"22","author":"Anttinen","year":"2020","journal-title":"Eur Urol Open Sci"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1111\/bju.15523","article-title":"Magnetic resonance imaging-guided transurethral ultrasound ablation for benign prostatic hyperplasia: 12-month clinical outcomes of a phase I study","volume":"129","author":"Viitala","year":"2022","journal-title":"BJU Int"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2013.04.039","article-title":"Whole-gland ablation of localized prostate cancer with high-intensity focused ultrasound: oncologic outcomes and morbidity in 1002 patients","volume":"65","author":"Crouzet","year":"2014","journal-title":"Eur Urol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2018.06.006","article-title":"A multicentre study of 5-year outcomes following focal therapy in treating clinically significant nonmetastatic prostate cancer","volume":"74","author":"Guillaumier","year":"2018","journal-title":"Eur Urol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2016.02.054","article-title":"Medium-term outcomes after whole-gland high-intensity focused ultrasound for the treatment of nonmetastatic prostate cancer from a multicentre registry cohort","volume":"70","author":"Dickinson","year":"2016","journal-title":"Eur Urol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/j.euf.2020.12.016","article-title":"Oncological long-term outcome after whole-gland high-intensity focused ultrasound for prostate cancer\u201321-yr follow-up","volume":"8","author":"Br\u00fcndl","year":"2022","journal-title":"Eur Urol Focus"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2022.01.005","article-title":"Cancer control outcomes following focal therapy using high-intensity focused ultrasound in 1379 men with nonmetastatic prostate cancer: a multi-institute 15-year experience","volume":"81","author":"Reddy","year":"2022","journal-title":"Eur Urol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1038\/s41391-021-00369-6","article-title":"Conventional radical versus focal treatment for localised prostate cancer: a propensity score weighted comparison of 6-year tumour control","volume":"24","author":"van Son","year":"2021","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1038\/s41391-020-00315-y","article-title":"Focal therapy compared to radical prostatectomy for non-metastatic prostate cancer: A propensity score-matched study","volume":"24","author":"Shah","year":"2021","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00251-0","article-title":"MRI-Guided focused ultrasound focal therapy for patients with intermediate-risk prostate cancer: a phase 2b, multicentre study","volume":"23","author":"Ehdaie","year":"2022","journal-title":"Lancet Oncol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000001362","article-title":"Magnetic resonance imaging-guided transurethral ultrasound ablation of prostate cancer","volume":"205","author":"Klotz","year":"2021","journal-title":"J Urol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(12)70121-3","article-title":"Focal therapy for localised unifocal and multifocal prostate cancer: a prospective development study","volume":"13","author":"Ahmed","year":"2012","journal-title":"Lancet Oncol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2015.06.018","article-title":"Focal high-intensity focused ultrasound targeted hemiablation for unilateral prostate cancer: a prospective evaluation of oncologic and functional outcomes","volume":"69","author":"Feijoo","year":"2016","journal-title":"Eur Urol"},{"key":"B58","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1038\/pcan.2015.55","article-title":"A prospective clinical trial of HIFU hemiablation for clinically localized prostate cancer","volume":"19","author":"Van Velthoven","year":"2016","journal-title":"Prostate Cancer prostatic Dis"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2016.09.039","article-title":"Focal high intensity focused ultrasound of unilateral localized prostate cancer: A prospective multicentric hemiablation study of 111 patients","volume":"71","author":"Rischmann","year":"2017","journal-title":"Eur Urol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2017.10.033","article-title":"Prospective multicenter phase II study on focal therapy (hemiablation) of the prostate with high intensity focused ultrasound","volume":"199","author":"Ganzer","year":"2018","journal-title":"J Urol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2019.06.043","article-title":"Focal high-intensity focussed ultrasound partial gland ablation for the treatment of localised prostate cancer: a report of medium-term outcomes from a single-center in the united kingdom","volume":"133","author":"Johnston","year":"2019","journal-title":"Urology"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000001126","article-title":"High intensity focused ultrasound hemigland ablation for prostate cancer: initial outcomes of a united states series","volume":"204","author":"Abreu","year":"2020","journal-title":"J Urol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000001015","article-title":"Prospective evaluation of focal high intensity focused ultrasound for localized prostate cancer","volume":"204","author":"Nahar","year":"2020","journal-title":"J Urol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-020-01723-9","article-title":"Focal therapy with high-intensity focused ultrasound for the localized prostate cancer for Asian based on the localization with MRI-TRUS fusion image-guided transperineal biopsy and 12-cores transperineal systematic biopsy: prospective analysis of oncological and functional outcomes","volume":"25","author":"Shoji","year":"2020","journal-title":"Int J Clin Oncol"},{"key":"B65","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta19490","article-title":"Ablative therapy for people with localised prostate cancer: a systematic review and economic evaluation","volume":"19","author":"Ramsay","year":"2015","journal-title":"Health Technol Assess"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2020.12.008","article-title":"A systematic review of focal ablative therapy for clinically localised prostate cancer in comparison with standard management options: limitations of the available evidence and recommendations for clinical practice and further research","volume":"4","author":"Bates","year":"2021","journal-title":"Eur Urol Oncol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1111\/bju.14710","article-title":"Medium-term oncological outcomes in a large cohort of men treated with either focal or hemi-ablation using high-intensity focused ultrasonography for primary localized prostate cancer","volume":"124","author":"Stabile","year":"2019","journal-title":"BJU Int"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2013.12.014","article-title":"Underutilization of local salvage therapy after radiation therapy for prostate cancer","volume":"32","author":"Tran","year":"2014","journal-title":"Urol Oncol: Semin Original Investi"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2020.11.010","article-title":"A systematic review and meta-analysis of local salvage therapies after radiotherapy for prostate cancer (MASTER)","volume":"80","author":"Valle","year":"2021","journal-title":"Eur Urol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.1043688\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,17]],"date-time":"2022-11-17T10:01:37Z","timestamp":1668679297000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.1043688\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,17]]},"references-count":69,"alternative-id":["10.3389\/fonc.2022.1043688"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2022.1043688","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,17]]},"article-number":"1043688"}}